PRGOPerrigo Company plc
Is the price fair?
Growth expectations in line with delivery. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~5% a year FCF growth. Moderate growth expectations are priced in.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What PRGO's price assumes
Today's price asks for 4.7% free cash flow growth a year; over the last three years Perrigo Company plc delivered −19%, so the price is ahead of the record.
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 5.4%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
- Growth the price implies
- +4.7%
Growth the price implies · The price pays for +4.7% free cash flow growth a year for a decade; the business has delivered −19% a year over the last three.
- Price / book
- 0.55
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 0.55
- EV / EBIToperating margin −38%: the multiple describes the denominator
- not meaningful
- EV / salesas of 2026-Q2
- 1.03
- Free cash flow, trailing twelve months
- $119M
- Market capitalisation138.8 million shares, counted Jul 31, 2026
- $2.21B
- 3-year revenue growth
- −3.6%
- 3-year free cash flow growth
- −19%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Drug Manufacturers, Specialty & Generic
Ranks #21 of 39 by RyuScore